23 May 2013 - 23 May 2013 - German Cenix BioScience and Swiss Debiopharm said today they will partner on the identification of predictive biomarkers.

The collaboration will utilise Cenix's know-how in combining high throughput screening with high content assays in cultured human cells, to identify predictive biomarkers for Debiopharm's preclinical oncology candidates.

Multi-parametric microscopy-based readouts established by Cenix using the Definiens XD image analysis platform will be used in various human cancer cell models to identify genes and pathways that either enhance or suppress the drug's therapeutic effects.

Financial details were not available.